{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:41:22Z","timestamp":1794850882375,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A151501173"],"award-info":[{"award-number":["2021A151501173"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR301696"],"award-info":[{"award-number":["NIHR301696"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202201020362"],"award-info":[{"award-number":["202201020362"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC- 1215-20014"],"award-info":[{"award-number":["BRC- 1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502800"],"award-info":[{"award-number":["2022YFC2502800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070955"],"award-info":[{"award-number":["82070955"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101117"],"award-info":[{"award-number":["82101117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017645","name":"Moorfields Eye Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.xcrm.2024.101524","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T10:40:27Z","timestamp":1714041627000},"page":"101524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucoma"],"prefix":"10.1016","volume":"5","author":[{"given":"Jiaxuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjie","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yu-Wai-Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9288-0767","authenticated-orcid":false,"given":"Xiulan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101524_bib1","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","article-title":"Glaucoma: now and beyond","volume":"402","author":"Jayaram","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101524_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in Adults\u2014Screening, Diagnosis, and Management: A Review","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101524_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.icu.0000156136.20570.eb","article-title":"Glaucoma medication and aqueous humor dynamics","volume":"16","author":"Crowston","year":"2005","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib4","first-page":"225","article-title":"The Diagnosis and Treatment of Glaucoma","volume":"117","author":"Schuster","year":"2020","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.xcrm.2024.101524_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14656566.2017.1328498","article-title":"Topical treatment of glaucoma: established and emerging pharmacology","volume":"18","author":"Dikopf","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.xcrm.2024.101524_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00002512-200320120-00008","article-title":"Brinzolamide: A Review of Its Use\u00a0in the Management of Primary Open-Angle Glaucoma and Ocular Hypertension","volume":"20","author":"Cvetkovic","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.xcrm.2024.101524_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2165\/00002512-199710050-00006","article-title":"Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension","volume":"10","author":"Balfour","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.xcrm.2024.101524_bib8","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.xcrm.2024.101524_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101524_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543776.2013.794788","article-title":"Antiglaucoma carbonic anhydrase inhibitors: a patent review","volume":"23","author":"Masini","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.xcrm.2024.101524_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1350-9462(99)00006-3","article-title":"Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors","volume":"19","author":"Sugrue","year":"2000","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.xcrm.2024.101524_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/138161208783877866","article-title":"The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents","volume":"14","author":"Mincione","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.xcrm.2024.101524_bib13","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1080\/14656566.2020.1795130","article-title":"Current and new pharmacotherapeutic approaches for glaucoma","volume":"21","author":"Shalaby","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.xcrm.2024.101524_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1208\/s12249-021-01977-0","article-title":"Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations","volume":"22","author":"Lanier","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xcrm.2024.101524_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/13543776.2019.1679117","article-title":"Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019","volume":"29","author":"Supuran","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.xcrm.2024.101524_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-94-007-7359-2_17","article-title":"Glaucoma and the applications of carbonic anhydrase inhibitors","volume":"75","author":"Scozzafava","year":"2014","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.xcrm.2024.101524_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100901","article-title":"Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma","volume":"82","author":"Kompella","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.xcrm.2024.101524_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/vop.12858","article-title":"Looking into the future: Gene and cell therapies for glaucoma","volume":"24","author":"Kom\u00e1romy","year":"2021","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/vop.12843","article-title":"Medical anti-glaucoma therapy: Beyond the drop","volume":"24","author":"Miller","year":"2021","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/ICU.0b013e32834371d2","article-title":"Gene therapy for glaucoma","volume":"22","author":"Demetriades","year":"2011","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1566523221666210423084233","article-title":"Gene Therapy in the Anterior Eye Segment","volume":"22","author":"Amador","year":"2022","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.xcrm.2024.101524_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41433-022-02169-1","article-title":"The application and progression of CRISPR\/Cas9 technology in ophthalmological diseases","volume":"37","author":"Hu","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xcrm.2024.101524_bib23","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9\u2013based treatment of myocilin-associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101524_bib24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ymthe.2019.12.012","article-title":"Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9","volume":"28","author":"Wu","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101524_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116140","article-title":"Developments of small molecules as inhibitors for carbonic anhydrase isoforms","volume":"39","author":"Buabeng","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.xcrm.2024.101524_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103557","article-title":"Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents","volume":"95","author":"Ghorai","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.xcrm.2024.101524_bib27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 Structures and Mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.xcrm.2024.101524_bib28","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/s41598-022-06430-1","article-title":"Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization","volume":"12","author":"Fierro","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101524_bib29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1751-7915.13534","article-title":"Dual sgRNA-directed gene deletion in basidiomycete Ganoderma lucidum using the CRISPR\/Cas9 system","volume":"13","author":"Liu","year":"2020","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101524_bib30","first-page":"419","article-title":"Carbonic anhydrase isoenzymes CA I and CA II in the human eye","volume":"27","author":"Wistrand","year":"1986","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2024.101524_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1559-0275-10-9","article-title":"Characterizing the normal proteome of human ciliary body","volume":"10","author":"Goel","year":"2013","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.xcrm.2024.101524_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.bi.64.070195.002111","article-title":"Human carbonic anhydrases and carbonic anhydrase deficiencies","volume":"64","author":"Sly","year":"1995","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.xcrm.2024.101524_bib33","first-page":"79","article-title":"An overview of the distribution and function of carbonic anhydrase in mammals","volume":"90","author":"Parkkila","year":"2000","journal-title":"EXS"},{"key":"10.1016\/j.xcrm.2024.101524_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3748\/wjg.v11.i2.155","article-title":"Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours","volume":"11","author":"Kivel\u00e4","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2024.101524_bib35","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2021-319530","article-title":"Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?","volume":"106","author":"Stoner","year":"2022","journal-title":"Br. J.\u00a0Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1113\/jphysiol.2005.102590","article-title":"Carbonic anhydrase gene expression in\u00a0CA II-deficient (Car2\u2212\/\u2212) and CA IX-deficient (Car9\u2212\/\u2212) mice","volume":"571","author":"Pan","year":"2006","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.xcrm.2024.101524_bib37","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fphys.2017.01108","article-title":"Deficiency of Carbonic Anhydrase II Results in a Urinary Concentrating Defect","volume":"8","author":"Krishnan","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.xcrm.2024.101524_bib38","doi-asserted-by":"crossref","first-page":"F869","DOI":"10.1152\/ajprenal.00344.2014","article-title":"Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility","volume":"307","author":"Hains","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.xcrm.2024.101524_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12964-019-0478-4","article-title":"Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment","volume":"17","author":"Annan","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.xcrm.2024.101524_bib40","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/neuonc\/noab156","article-title":"A comparative integrated multi-omics analysis identifies CA2 as a novel target for chordoma","volume":"23","author":"Meng","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2024.101524_bib41","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.4049\/jimmunol.2100665","article-title":"Carbon Dioxide Sensing by Immune Cells Occurs through Carbonic Anhydrase 2-Dependent Changes in Intracellular pH","volume":"208","author":"Strowitzki","year":"2022","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101524_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-0290-4_1","article-title":"RNA and CRISPR Interferences: Past, Present, and Future Perspectives","volume":"2115","author":"Sioud","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101524_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","article-title":"CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases","volume":"29","author":"Sharma","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101524_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.62.12.7","article-title":"Using CRISPR Interference as a Therapeutic Approach to Treat TGF\u03b22-Induced Ocular Hypertension and Glaucoma","volume":"62","author":"Rayana","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2024.101524_bib45","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/APO.0000000000000646","article-title":"Minimally Invasive Glaucoma Surgery: Latest Developments and Future Challenges","volume":"12","author":"Chan","year":"2023","journal-title":"Asia. Pac. J. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/APO.0000000000000637","article-title":"Outcomes of Goniotomy With or Without Secondary Intraocular Lens Implantation in Pediatric Glaucoma Following Cataract Surgery: A Prospective Pilot Study","volume":"12","author":"Zhang","year":"2023","journal-title":"Asia. Pac. J. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib47","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib48","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.xcrm.2024.101524_bib49","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/14740338.2017.1346083","article-title":"Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation","volume":"16","author":"Lusthaus","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.xcrm.2024.101524_bib50","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.ymthe.2017.03.008","article-title":"Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward","volume":"25","author":"Bennett","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101524_bib51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.exer.2005.03.010","article-title":"Carbonic anhydrase XIV identified as the membrane CA in mouse retina: strong expression in M\u00fcller cells and the RPE","volume":"81","author":"Ochrietor","year":"2005","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.xcrm.2024.101524_bib52","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1167\/iovs.13-13534","article-title":"Carbonic anhydrase inhibitors in corneal endothelial transport","volume":"55","author":"Malikowski","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2024.101524_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14756366.2019.1705293","article-title":"Design, synthesis and biological evaluation of carbohydrate-based sulphonamide derivatives as topical antiglaucoma agents through selective inhibition of carbonic anhydrase II","volume":"35","author":"Hou","year":"2020","journal-title":"J.\u00a0Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.xcrm.2024.101524_bib54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.xcrm.2024.101524_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007467","article-title":"A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat M\u00fcller cells","volume":"4","author":"Klimczak","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101524_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.570917","article-title":"Comparison of CRISPR\/Cas Endonucleases for in\u00a0vivo Retinal Gene Editing","volume":"14","author":"Li","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101524_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","article-title":"Delivery Strategies of the\u00a0CRISPR-Cas9 Gene-Editing System for Therapeutic Applications","volume":"266","author":"Liu","year":"2017","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.xcrm.2024.101524_bib58","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.3390\/molecules25194405","article-title":"The Effect of Nanoparticles on the Structure and Enzymatic Activity of Human Carbonic Anhydrase I and II","volume":"25","author":"Cabaleiro-Lago","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2024.101524_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-019-0088-8","article-title":"Optimizing genome editing strategy by primer-extension-mediated sequencing","volume":"5","author":"Yin","year":"2019","journal-title":"Cell Discov."},{"key":"10.1016\/j.xcrm.2024.101524_bib60","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gky354","article-title":"CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens","volume":"46","author":"Concordet","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101524_bib61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124001939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124001939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:16:16Z","timestamp":1778919376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124001939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666379124001939"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101524","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101524"}}